The Clinical Evidence Investors Actually Care About

Statistical significance might get you published-but it won’t necessarily get you funded.

For early-stage MedTech companies, one of the most common (and costly) mistakes is assuming that positive clinical or statistical results automatically translate into commercial success. In reality, investors, regulators, payers, and clinicians all evaluate evidence differently-and what counts as “good enough” changes dramatically as your company matures.

In this live webinar, Jon Bergsteinsson and Páll Jóhannesson, co-founders of Greenlight Guru Clinical, share hard-earned insights from building, operating, and evaluating clinical programs across the MedTech lifecycle.

Drawing on Jon’s experience as a former MedTech founder and investor, alongside Páll’s deep background in clinical operations and data integrity, they unpack how clinical evidence is actually assessed by investors, regulators, and payers - and why so many promising devices stall despite “good data.”

In this session, you will learn about:

• The three different types of significance-and why confusing them can derail funding
• What “good enough” clinical evidence really looks like at Pre-Seed, Seed, and Series A stages
• How investors interpret the same dataset in very different ways
• The most common clinical evidence red flags that slow or kill deals
• How strong clinical operations can become a commercial advantage, not just a compliance requirement